RxDoctor Payments Data

Joseph Chipman, MD

Neurology · Charlotte, NCNPI 1871756759

Payments from drug & device makers

$128,361in general payments, 2019–2025

Across 156 payments — averaging $822.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$75K
  • AstraZeneca$45K
  • Amgen$4K
  • UCB, Inc.$3K
  • Akcea Therapeutics, Inc.$571
  • Argenx US, Inc.$325
  • plus $139 from 1 others

What the payments were for

  • Consulting fees$2,2402%
  • Speaking & faculty fees$108,01091%
  • Travel & lodging$5,4195%
  • Food & beverage$2,4922%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)80$74,565
AstraZeneca66$45,289
Amgen3$4,112
UCB, Inc.3$3,360
Akcea Therapeutics, Inc.2$571
Argenx US, Inc.1$325
Nevro Corp.1$139

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,361 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$84,954
Medicare patients
304
Services billed
2,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab22$1,614,833
UltomirisRavulizumab-Cwvz27$1,115,284
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5086$1,043,664
BotoxOnabotulinumtoxina165$229,920
Nurtec OdtRimegepant Sulfate11$23,418
Aimovig AutoinjectorErenumab-Aooe26$19,248
Pyridostigmine Bromide107$10,453
NamzaricMemantine Hcl/Donepezil Hcl15$10,255
ZonegranZonisamide13$9,150
Lacosamide21$8,255
Gabapentin388$7,025
Mycophenolate Mofetil35$4,034
Pregabalin132$2,616
Tizanidine Hcl81$1,570
Pramipexole DihydrochloridePramipexole Di-Hcl32$1,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$325$1,614,83322 claims
AstraZenecaUltomiris$45,289$1,115,28427 claims
AbbVieBotox, Namzaric$74,565$240,174180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →